Novo Nordisk’s zenagamtide shows 14.6% weight-loss in mid-stage diabetes study, ETPharma
Plainsboro: Novo Nordisk’s next-generation weight-loss candidate, zenagamtide has delivered an average weight-loss of up to 14.6 per cent…
Browsing Tag